Trials / Completed
CompletedNCT00121069
Study of Escitalopram in the Treatment of Specific Phobia
Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 12 (planned)
- Sponsor
- Connor, Kathryn M., M.D. · Individual
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.
Detailed description
This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Escitalopram |
Timeline
- Start date
- 2002-09-01
- Completion
- 2004-09-01
- First posted
- 2005-07-21
- Last updated
- 2005-07-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00121069. Inclusion in this directory is not an endorsement.